Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide (VI or VIT) in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma

NCT01355445 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT01355445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01355445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide (VI or VIT) in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma
Lead sponsor
Centre Oscar Lambret
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2012
Completion date
May 31, 2019
Enrollment
120 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

rhabdomyosarcoma